-
公开(公告)号：US11254951B2
公开(公告)日：2022-02-22
申请号：US16030018
申请日：2018-07-09
申请人： CureVac AG
发明人： Andreas Thess
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR) element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a ribosomal protein gene for enhancing, stabilizing and/or prolonging protein expression from a nucleic acid sequence comprising such 3′-UTR element.
-
公开(公告)号：US11149278B2
公开(公告)日：2021-10-19
申请号：US15534496
申请日：2015-12-11
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Stefanie Grund
IPC分类号： C12N15/67 , C12N15/68 , C12N15/85 , A61K39/145 , A61K39/12 , A61K39/205 , A61K48/00 , A61K39/00
摘要： The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
-
公开(公告)号：US10898584B2
公开(公告)日：2021-01-26
申请号：US15142082
申请日：2016-04-29
申请人： CureVac Ag
发明人： Thomas Schlake , Andreas Thess
摘要： The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
-
公开(公告)号：US10080809B2
公开(公告)日：2018-09-25
申请号：US14388224
申请日：2013-03-27
申请人： CureVac AG
发明人： Andreas Thess
CPC分类号： A61K48/0066 , A61K38/00 , A61K39/00 , C12N15/67 , C12N15/85 , C12N2830/50 , C12N2830/85 , C12N2840/105
摘要： The invention relates to an artificial nucleic acid molecule comprising at least one 5′UTR element which is derived from a TOP gene, at least one open reading frame and optionally at least one 3′UTR element comprising a nucleic acid sequence which is preferably derived from the 3′UTR of a gene providing a stable mRNA, such as an albumin gene, or from a variant of the 3′UTR of a gene providing a stable mRNA. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
-
公开(公告)号：US11286492B2
公开(公告)日：2022-03-29
申请号：US17408332
申请日：2021-08-20
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Stefanie Grund
IPC分类号： C12N15/67 , C12N15/68 , C12N15/85 , A61K39/145 , A61K39/12 , A61K39/205 , A61K48/00 , A61K39/00
摘要： The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.
-
公开(公告)号：US10799577B2
公开(公告)日：2020-10-13
申请号：US15892330
申请日：2018-02-08
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Jochen Probst
摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US10682406B2
公开(公告)日：2020-06-16
申请号：US15892356
申请日：2018-02-08
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Jochen Probst
摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US10232024B2
公开(公告)日：2019-03-19
申请号：US14378591
申请日：2013-02-15
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Jochen Probst
摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of allergies or autoimmune diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US10166283B2
公开(公告)日：2019-01-01
申请号：US15465322
申请日：2017-03-21
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Jochen Probst
IPC分类号： A61K48/00 , A61K38/00 , A61K39/145 , A61K39/00 , C12N15/67 , C12N15/63 , A61K39/12 , C12N7/00
摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
公开(公告)号：US10912826B2
公开(公告)日：2021-02-09
申请号：US16938136
申请日：2020-07-24
申请人： CureVac AG
发明人： Andreas Thess , Thomas Schlake , Jochen Probst
摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.032 秒)
